Background/Aims: Hemodialysis (HD) patients are prone to developing peptic ulcers. However, of all the risk factors associated with peptic ulcers, none have been shown to be more prevalent in HD patients than in the general population. However, salivary epidermal growth factor (EGF) may play a role in peptic ulcer diseases. Methods: Salivary EGF levels and bioactivities were assayed in 47 maintenance HD patients and 30 normal controls, and the molecular weights of EGF were assessed using high-performance liquid chromatography (HPLC). Results: Salivary EGF levels were not different between both groups of subjects (4.2 ± 0.34 vs. 5 ± 0.54 ng/mg protein, NS), and HPLC revealed that salivary EGF in both groups had similar molecular weights. However, salivary EGF bioactivity was significantly depressed in the HD patients as compared to the normal controls (0.59 ± 0.08 vs. 1.55 ± 0.15 ng/mg protein, p < 0.01). Stepwise multiple regression showed that the low salivary EGF levels were associated with female gender (p < 0.05), while low salivary EGF bioactivity was associated with HD per se (p < 0.05). In the 22 HD patients who underwent gastric endoscopy, salivary EGF bioactivity was significantly lower in those with peptic ulcers than in those without (0.38 ± 0.08 vs. 0.69 ± 0.08 ng/mg protein, p < 0.05). Conclusion: Decreased salivary EGF bioactivity may contribute to peptic ulcer disease among maintenance HD patients.

Keywords:
Hemodialysis, Saliva, Epidermal growth factor, Peptic ulcer
1.
Mandelbrot DA, Lazarus JM: Gastrointestinal complications in dialysis patients; in Jacobs C, Kjellstrand CM, Koch KM, Winchester JF (eds): Replacement of Renal Function by Dialysis, ed 4. Dordrecht, Kluwer Academic, 1996, pp 1049–1050.
2.
Var C, Gultekin F, Candan F, Turkay C, Sencan M, Icagasioglu S, Dokmetas S, Topcu S, Icli F, Var F, Eglimez R: The effects of hemodialysis on duodenal and gastric mucosal changes in uremic patients. Clin Nephrol 1996;45:310–314.
3.
Calabrò A, Milani S, Paladini I, Orsini B, Salvadori G, Surrenti C: Role of epidermal growth factor in peptic ulcer healing. Dig Dis Sci 1995;40:2497–2504.
4.
Maccini DM, Veit BC: Salivary epidermal growth factor in patients with and without acid peptic disease. Am J Gastroenterol 1990;85:1102–1104.
5.
Hansen G, Muller C, Sinha P: Gastric ulcer is accompanied by a decrease of epidermal growth factor in gastric juice and saliva. J Clin Chem Clin Biochem 1989;27:539–545.
6.
Lynch DA, Mapstone NP, Lewis F, Pentith J, Axon AT, Dixon MF, Quirke P: Serum and gastric luminal epidermal growth factor in Helicobacter pylori-associated gastritis and peptic ulcer disease. Helicobacter 1996;1:219–226.
7.
Imai S, Itoh M, Yokoyama Y, Joh T, Takeuchi T: Effect of proton pump inhibitor, in combination with epidermal growth factor, on the healing of chronic gastric ulcer in submandibular gland removed rats. Nippon Rinsho 1992;50:39–44.
8.
Sein KT, Arumainayagam G: Correlation between serum urea and salivary urea. Clin Chem 1987;33:2303–2304.
9.
Lev-Ran A, Hwang DL, Ahmad B, Bixby H: Immunoreactive epidermal growth factor in serum, plasma, platelets, and urine in patients on chronic dialysis. Nephron 1991;57:164–166.
10.
Lowry R, Kann L, Collins JL, Kolbe LJ: The effect of socioeconomic status on chronic disease risk behaviors among US adolescents. JAMA 1996;276:792–797.
11.
Guh JY, Lai YH, Yang CY, Chen SC, Chuang WL, Hsu TC, Chen HC, Chang WY, Tsai JH: Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995;69:459–465.
12.
Yeh YC, Guh JY, Yeh J, Yeh HW: Transforming growth factor type alpha in normal human adult saliva. Mol Cell Endocrinol 1989;67:247–255.
13.
Orsini B, Brocchi A, Calabrò A, Fedi P, Tommasi MS, Surrenti C: Radioimmunoassay of epidermal growth factor in human saliva and gastric juice. Clin Biochem 1991;24:135–141.
14.
Guh JY, Lai YH, Shin SJ, Chuang LY, Tsai JH: Epidermal growth factor in renal hypertrophy in streptozotocin-diabetic rats. Nephron 1991;59:641–647.
15.
Dutta SK, Orestes M, Vengulekur S, Kwo P: Ethanol and human saliva: Effect of chronic alcoholism on flow rate, composition, and epidermal growth factor. Am J Gastroenterol 1992;87:350–354.
16.
Schubert TT, Bologna SD, Nensey Y, Schubert AB, Mascha EJ, Ma CK: Ulcer risk factors: Interactions between Helicobacter pylori infection, nonsteroidal use, and age. Am J Med 1993;94:413–418.
17.
Jones MK: Gastrointestinal mucosal regeneration: Role of growth factors. Front Biosci 1999;4:D303–D309.
18.
Russo F, Messa C, Amati L, Caradonna L, Leoci C, Di Matteo G, Jirillo E, Di Leo A: The influence of Helicobacter pylori eradication on the gastric mucosal content of epidermal growth factor, transforming growth factor-alpha, and their common receptor. Scand J Gastroenterol 1998;33:271–275.
19.
Konturek PC, Bobrzynski A, Konturek SJ, Bielanski W, Faller G, Kirchner T, Hahn EG: Epidermal growth factor and transforming growth factor-alpha in duodenal ulcer and non-ulcer dyspepsia patients before and after Helicobacter pylori eradication. Scand J Gastroenterol 1998;33:143–151.
20.
Messa C, Di Leo A, Greco B, Caradonna L, Amati L, Linsalata M, Giorgio I, Jirillo E: Successful eradicating treatment of Helicobacter pylori in patients with chronic gastritis: Gastric levels of cytokines, epidermal growth factor and polyamines before and after therapy. Immunopharmacol Immunotoxicol 1996;18:1–13.
21.
Degogo-Jack S, Rodger RSC, Kendall-Taylor P: Increased salivary concentration of human epidermal growth factor in patients undergoing CAPD. Perit Dial Int 1991;11:270–273.
22.
Gilchrist W, Burkhalter E, Eaton C, Schaudies RP, Maydonovitch C, Andrada F, Maged AR, Wong RK: The effect of indomethacin on the secretion of human salivary epidermal growth factor. Am J Gastroenterol 1994;89:97–100.
23.
Jones PDE, Hudson N, Hawkey CJ: Depression of salivary epidermal growth factor by smoking. BMJ 1992;304:480–481.
24.
Kho HS, Lee SW, Chung SC, Kim YK: Oral manifestations and salivary flow rate, pH, and buffer capacity in patients with end-stage renal disease undergoing hemodialysis. Oral Surg Oral Med Oral Pathol 1999;88:316–319.
25.
Fujiwara Y, Schmassmann A, Arakawa T, Halter F, Tarnawski A: Indomethacin interferes with epidermal growth factor binding and proliferative response of gastric Kato III cells. Digestion 1995;56:364–369.
26.
Fujiwara Y, Wyle F, Arakawa T, Domek MJ, Fukuda T, Kobayashi K, Tarnawski A: Helicobactor pylori culture supernatant inhibits binding and proliferative response of human gastric cells to epidermal growth factor: Implications for H. pylori interference with ulcer healing? Digestion 1997;58:299–303.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.